DE971033T1 - Prüfung und Modell für Alzheimers-Krankheit - Google Patents

Prüfung und Modell für Alzheimers-Krankheit

Info

Publication number: DE971033T1
Authority: DE; Germany
Prior art keywords: amino acid; model; exam; disease; alzheimer
Prior art date: 1991-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE0971033T

Other languages

English (en)

Inventor

John Anthony Hardy

Marie-Christin Chartier-Harlin

Alison Mary Goate

Michael John Owen

Michael John Mullan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Imperial College of Science Technology and Medicine

Original Assignee

Imperial College of Science Technology and Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2001-05-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE971033(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Imperial College of Science Technology and Medicine filed Critical Imperial College of Science Technology and Medicine

2001-05-03 Publication of DE971033T1 publication Critical patent/DE971033T1/de

Status Pending legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

DE0971033T 1991-01-21 1992-01-21 Prüfung und Modell für Alzheimers-Krankheit Pending DE971033T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease

Publications (1)

Publication Number	Publication Date
DE971033T1 true DE971033T1 (de)	2001-05-03

Family

ID=26298303

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Country Status (10)

Country	Link
US (3)	US5877015A (de)
EP (2)	EP0971033B1 (de)
JP (3)	JP3510244B2 (de)
AT (2)	ATE286971T1 (de)
AU (1)	AU652997B2 (de)
CA (2)	CA2372251A1 (de)
DE (3)	DE971033T1 (de)
DK (2)	DK0971033T3 (de)
ES (2)	ES2335720T3 (de)
WO (1)	WO1992013069A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE286971T1 (de)	1991-01-21	2005-01-15	Elan Pharm Inc	Prüfung und modell für alzheimers-krankheit
WO1993010459A1 (en) *	1991-11-12	1993-05-27	The University Of Melbourne	A method for assaying and treating alzheimer's disease
JPH06511387A (ja)	1991-12-24	1994-12-22	アイシス・ファーマシューティカルス・インコーポレーテッド	β−アミロイド調節のための組成物および方法
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
AU671093B2 (en) *	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
JPH09507746A (ja)	1993-10-27	1997-08-12	アテナニューロサイエンシズ，インコーポレイティド	Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
CA2182311A1 (en)	1994-01-27	1995-08-03	Karen Hsiao	Transgenic non-human mammals with progressive neurologic disease
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1996006927A1 (en) *	1994-09-01	1996-03-07	Merck & Co., Inc.	Transgenic animal expressing a familial form of human amyloid precursor protein
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
WO1996040895A1 (en) *	1995-06-07	1996-12-19	Athena Neurosciences, Inc.	Method for identifying alzheimer's disease therapeutics using transgenic animal models
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
BR9813105A (pt) *	1997-10-24	2000-08-15	Aventis Pharma Sa	Polipeptìdeo, composto não peptìdico ou não exclusivamente peptìdico, sequência nucleotìdica, processo de preparação de um polipeptìdeo e de demonstração ou de isolamento de compostos capazes de inibir, pelo menos em parte, a interação entre uma presenilina e o precursor do peptìdeo beta-amilóide e/ou o peptìdeo beta-amilóide, célula hospedeira, testes de interação entre uma presenilina e o precursor do peptìdeo beta-amilóide e/ou o peptìdeo beta-amilóide e de verificação de moléculas capazes de inibir a interação entre uma presenilina e o percusor do peptìdeo beta-amilóide e/ou o peptìdeo beta-amilóide, ligante, vìrus recombinante defectivo, vetor, composição farmacêutica, utilização dos polipetìdeos e da sequência nucleotìdica e cassete de expressão
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en)	1997-12-02	2004-06-01	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20070013361A (ko)	1998-09-24	2007-01-30	파마시아 앤드 업존 캄파니 엘엘씨	알츠하이머병 세크레타제
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
WO2000047618A2 (en)	1999-02-10	2000-08-17	Elan Pharmaceuticals, Inc.	HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
US6355425B1 (en)	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
WO2001047944A2 (en) *	1999-12-28	2001-07-05	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1265849B1 (de)	2000-03-23	2006-10-25	Elan Pharmaceuticals, Inc.	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
KR20030058959A (ko) *	2000-06-30	2003-07-07	엘란 파마슈티칼스, 인크.	알츠하이머병을 치료하기 위한 화합물
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
WO2002002769A1 (en) *	2000-07-06	2002-01-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel app mutation associated with an unusual alzheimer's disease pathology
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002314914A1 (en) *	2001-06-01	2002-12-16	Elan Pharmaceuticals, Inc.	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
JP2004532894A (ja)	2001-06-13	2004-10-28	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療するためのアミンジオール
BR0210721A (pt) *	2001-06-27	2004-07-20	Elan Pharm Inc	Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
WO2003006453A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Aminediols for the treatment of alzheimer's disease
CA2453444A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Diaminediols for the treatment of alzheimer's disease
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
US7244755B2 (en)	2001-10-04	2007-07-17	Pharmacia & Upjohn Company	Hydroxypropylamines
BR0214035A (pt) *	2001-11-08	2005-04-26	Elan Pharm Inc	Composto
EP1448177A1 (de) *	2001-11-19	2004-08-25	Elan Pharmaceuticals, Inc.	Aminodiole zur behandlung von alzheimische krankheit
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
CA2477002A1 (en) *	2002-02-27	2003-09-04	Merck & Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
AU2003303141A1 (en) *	2002-04-30	2004-07-22	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer's disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
CA2507484A1 (en) *	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
CA2513722A1 (en)	2003-02-01	2004-08-19	Neuralab Limited	Active immunization to generate antibodies to soluble a-beta
CL2004000848A1 (es) *	2003-04-21	2005-01-28	Elan Pharmaceuticals Inc Pharm	Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
EP1615892A2 (de) *	2003-04-21	2006-01-18	Elan Pharmaceuticals, Inc.	Benzamid-2-hydroxy-3-diaminoalkane
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
CA2553973A1 (en) *	2004-01-21	2005-08-04	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US20050239832A1 (en) *	2004-03-09	2005-10-27	Varghese John	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087215A1 (en)	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
EP1735293A2 (de) *	2004-03-09	2006-12-27	Elan Pharmaceuticals, Inc.	Substituierte hydroxyethylamine als aspartylproteaseinhibitoren
CA2558034A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
WO2005110422A2 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
JP2008505929A (ja) *	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2006010095A2 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
EP1802574A2 (de) *	2004-08-27	2007-07-04	Elan Pharmaceuticals Inc.	Verfahren zur behandlung von amyloidose mit ethanolcyclicaminderivat-aspartylproteasehemmern
JP2008519282A (ja) *	2004-11-05	2008-06-05	ワイス	アルツハイマー病治療薬をスクリーニングするための画像診断モダリティー
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
WO2006122187A2 (en)	2005-05-10	2006-11-16	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
US20080293680A1 (en) *	2005-08-03	2008-11-27	Stefan Peters	Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
EP1915339A1 (de) *	2005-08-11	2008-04-30	Boehringer Ingelheim International GmbH	Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
WO2007017509A1 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Verbindungen zur behandlung der alzheimer erkrankung
CA2618474A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Compounds for treating alzheimer's disease
WO2007017511A2 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Verbindungen zur behandlung der alzheimer erkrankung
WO2007047306A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007092839A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7868022B2 (en)	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2009017467A1 (en)	2007-07-27	2009-02-05	Elan Pharma International Limited	Treatment of amyloidogenic diseases
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
CA2653628C (en)	2006-06-01	2015-07-14	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
CN101541950A (zh)	2006-07-13	2009-09-23	惠氏公司	糖蛋白的产生
FI3851447T3 (fi)	2006-10-12	2023-11-15	Bellus Health Inc	Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
ES2541546T3 (es)	2006-11-03	2015-07-21	Wyeth Llc	Sustancias que inhiben la glucólisis en cultivo celular
ES2728912T3 (es)	2007-03-02	2019-10-29	Wyeth Llc	Uso de cobre y glutamato en cultivo celular para la producción de polipéptidos
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
KR101461659B1 (ko)	2007-05-11	2014-11-17	토마스 제퍼슨 유니버시티	신경변성 질환 및 장애의 치료 및 예방 방법
WO2009007300A2 (en)	2007-07-06	2009-01-15	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
JP2011510989A (ja) *	2008-01-28	2011-04-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	β−セクレターゼ（ＢＡＣＥ）の阻害物質として有用な６−置換−チオ−２−アミノ−キノリン誘導体
AU2009209147B2 (en) *	2008-01-29	2013-03-14	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
US20110166197A1 (en) *	2008-02-19	2011-07-07	Edunn Biotechnology, Inc.	Antisense Modulation Of Amyloid Beta Protein Expression
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
US10449177B2 (en)	2010-08-19	2019-10-22	Buck Institute For Research On Aging	Methods of treating mild cognitive impairment (MCI) and related disorders
WO2013142370A1 (en)	2012-03-19	2013-09-26	Varghese John	APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
JP5918909B2 (ja)	2012-06-25	2016-05-18	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	標的化治療薬
EP3653609B1 (de)	2013-02-12	2024-04-03	Buck Institute for Research on Aging	Hydantoine als modulatoren von bace-vermittelter app-verarbeitung
EP2978446B1 (de)	2013-03-27	2020-03-04	The General Hospital Corporation	Anti-cd33 antikörper zur behandlung von morbus alzheimer
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
US11168369B2 (en)	2014-11-25	2021-11-09	The Brigham And Women's Hospital, Inc.	Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US10683552B2 (en)	2014-11-25	2020-06-16	Presidents And Fellows Of Harvard College	Clonal haematopoiesis
KR20180090778A (ko)	2015-08-27	2018-08-13	난트뉴로, 엘엘씨	App-선택적 bace 억제를 위한 조성물 및 그의 용도
JP7027341B2 (ja)	2016-05-12	2022-03-01	バック・インスティテュート・フォー・リサーチ・オン・エイジング	Ａｐｐの正常なプロセシングを促進する化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
AU606320B2 (en) *	1985-11-01	1991-02-07	International Genetic Engineering, Inc.	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3702789A1 (de) *	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
WO1989006689A1 (en) *	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
CA2055435A1 (en)	1989-05-10	1990-11-11	Eli Gilboa	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (de) *	1990-04-10	1991-10-16	Miles Inc.	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
CA2079880A1 (en) *	1990-04-24	1991-10-25	William E. Van Nostrand	Purification, detection and methods of use of protease nexin-2
ES2217250T3 (es) *	1990-06-15	2004-11-01	Scios Inc.	Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
AU8215391A (en) *	1990-06-29	1992-01-23	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
ATE286971T1 (de) *	1991-01-21	2005-01-15	Elan Pharm Inc	Prüfung und modell für alzheimers-krankheit
AU2765992A (en) *	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
AU671093B2 (en) *	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
- 1992-01-21 EP EP99109196A patent/EP0971033B1/de not_active Revoked
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en active IP Right Grant
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 EP EP92903304A patent/EP0568575B2/de not_active Expired - Lifetime
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
WO1992013069A1 (en)	1992-08-06
DE69233774D1 (de)	2009-12-10
EP0971033B1 (de)	2009-10-28
AU652997B2 (en)	1994-09-15
EP0568575B2 (de)	2010-11-03
CA2101774A1 (en)	1992-07-22
EP0971033A3 (de)	2003-11-12
ES2335720T3 (es)	2010-03-31
JP3574432B2 (ja)	2004-10-06
AU1169492A (en)	1992-08-27
ES2236682T5 (es)	2011-03-31
ATE447016T1 (de)	2009-11-15
JP3510244B2 (ja)	2004-03-22
ATE286971T1 (de)	2005-01-15
CA2101774C (en)	2011-01-04
JPH06504441A (ja)	1994-05-26
DK0568575T3 (da)	2005-05-23
EP0568575B1 (de)	2005-01-12
DE69233468D1 (de)	2005-02-17
JP2002306195A (ja)	2002-10-22
EP0568575A1 (de)	1993-11-10
DE69233468T2 (de)	2005-12-22
DK0971033T3 (da)	2009-12-14
ES2236682T3 (es)	2005-07-16
US6300540B1 (en)	2001-10-09
US20030165958A1 (en)	2003-09-04
CA2372251A1 (en)	1992-08-06
DE69233468T3 (de)	2011-05-05
JP2004261187A (ja)	2004-09-24
US5877015A (en)	1999-03-02
EP0971033A2 (de)	2000-01-12
DK0568575T4 (da)	2010-12-20

Publication	Publication Date	Title
DE69233774D1 (de)	2009-12-10	Prüfung und Modell für Alzheimers-Krankheit
DE69839808D1 (de)	2008-09-11	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
DK0868519T3 (da)	2006-05-08	Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
ES2170104T3 (es)	2002-08-01	Inhibidores de la produccion de proteinas de beta-amiloide.
ATE239797T1 (de)	2003-05-15	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE3852490D1 (de)	1995-01-26	Kategorie-erkennungssystem für analogbilder.
DK0528932T3 (da)	1996-07-01	Protein associeret med akut pancreatitis og midler til diagnose af akut pancreatitis
NO931889L (no)	1993-11-29	Protease og beslektede DNA-forbindelser
DE69333872T2 (de)	2006-06-14	Sonde zur Diagnose einer ansteckenden Krankheit verursacht durch Escherichia coli, Klebsiella pneumoniae oder Enterobacter cloacae
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60133661D1 (de)	2008-05-29	Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
DE68925275D1 (de)	1996-02-08	Endotoxin-bindeprotein und dessen verwendung
EP0716591A4 (de)	1998-02-04	Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
DE50108670D1 (de)	2006-04-06	Verwendung von neuregulin-beta als indikator und/oder target
ATE312914T1 (de)	2005-12-15	Rdgb-proteine
DK0592600T3 (da)	2000-04-17	Protein S polypeptider og anvendelse deraf
WO2023173009A3 (en)	2023-10-26	Wild-derived mouse models of alzheimer's disease
DE69519654T2 (de)	2001-05-17	htFIIIA Gen
DE59009360D1 (de)	1995-08-10	Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.